[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613918":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":32,"collaborators":7,"id":34,"slug":7,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":39,"eligibilityCriteria":40,"healthyVolunteers":35,"sex":41,"minAge":42,"maxAge":43,"enrollmentInfo":44,"targetDuration":7,"studyType":47,"phases":7,"briefSummary":48,"conditions":49,"keywords":55,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"University of Alberta","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Krista Jong, RD, BSc","CONTACT","780-492-9010","glimmer@ualberta.ca",[15],{"facility":16,"status":17,"city":18,"state":19,"zip":20,"country":21,"countryCode":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":29},"Mazankowski Alberta Heart Institute","RECRUITING","Edmonton","Alberta","T6G 0M9","Canada","CA",{"type":24,"coordinates":25},"Point",[26,27],-113.46871,53.55014,{"lat":27,"lon":26},[30],{"name":31,"role":11,"phone":12,"phoneExt":7,"email":13},"Krista Jong",{"type":33,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100613918",false,"NCT07272837","Impact of Semaglutide (Ozempic\u002FWegovy®) on Heart and Muscle Mass","GLP-1 Receptor Agonist-Induced Loss and Impairment of Muscle Mass - Evaluation of Response","GLIMMER","Inclusion Criteria:\n\n* Adults 18-80 years of age\n* Starting semaglutide for type 2 diabetes or weight loss\n* Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment)\n\nExclusion Criteria:\n\n* Current use of semaglutide for more than 2 weeks\n* Major recent heart issues or other severe health conditions\n* Concerns related to MRI use (including magnetic implants, pacemaker, severe claustrophobia)\n* Dependence on a mobility aid (unable to participate in exercise MRI)","ALL","18 Years","80 Years",{"count":45,"type":46},50,"ESTIMATED","OBSERVATIONAL","The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss.\n\nThis study involves (3) in-person study visits. At each visit, participants will be asked to:\n\n* Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs.\n* Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength.\n* Complete questionnaires related to demographics, health information, physical activity, and nutrition.\n* Have a blood sample collected from a vein in your arm.\n* Have your blood levels assessed through three finger pricks.\n* Complete three days of food records.",[50,51,52,53,54],"Type 2 Diabetes","Obesity","Semaglutide","GLP-1","Diabetes",[52,50,54,51,56,57,58,59,60,53,61,62],"Body Composition","Muscle Mass","Skeletal Muscle Mass","Cardiac Muscle Mass","GLP-1 Receptor Agonist","MRI","Magnetic Resonance Imaging","2026-04-15",{"date":65,"type":66},"2026-04-20","ACTUAL",{"date":68,"type":46},"2026-04-14",{"date":70,"type":46},"2028-04-30",{"name":5,"class":6},1]